Par Pharmaceutical, headquartered in Chestnut Ridge, NY, develops, manufactures and markets safe, innovative and cost-effective generic pharmaceutical products that help improve patient quality of life. Par offers differentiated, specialty dosage and sterile injectable drug products and is advancing a R&D pipeline of potential new products.
The recent combination of the Qualitest and Par businesses (known collectively as Par Pharmaceutical) expands Endo's generics business to a top five industry leader. Par Pharmaceutical is an operating company of Endo International plc (NASDAQ: ENDP) (TSX: ENL), a global specialty pharmaceutical company focused on improving patients' lives while creating shareholder value.